Showing results (1-10 of 512) with videos related to
Sort By:
Pageof 52
Frontiers in Endocrinology|February 14, 2022
The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort StudyRikke Viggers, Zheer Al-Mashhadi, Jakob Starup-Linde, et al.Frontiers in Endocrinology|December 6, 2021
Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control StudyRikke Viggers, Zheer Al-Mashhadi, Jakob Starup-Linde, et al.Bone|March 25, 2023
Discrepancies in type of first major osteoporotic fracture and anti-osteoporotic therapy in elderly people with type 2 diabetes mellitus: A retrospective Danish cohort studyRikke Viggers, Jakob Starup-Linde, Peter VestergaardFrontiers in Endocrinology|September 5, 2022
SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort studyZheer Kejlberg Al-Mashhadi, Rikke Viggers, Jakob Starup-Linde, et al.Current Osteoporosis Reports|August 10, 2019
Osteoglycin and Bone-a Systematic ReviewJakob Starup-Linde, Rikke Viggers, Aase HandbergFrontiers in Endocrinology|October 27, 2022
The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort studyZheer Kejlberg Al-Mashhadi, Rikke Viggers, Rasmus Fuglsang-Nielsen, et al.Current Drug Safety|November 13, 2013
Diabetes, cancer and treatment - a mini-reviewPeter Vestergaard, Jakob Starup-LindeBone|February 28, 2015
Biochemical bone turnover markers in diabetes mellitus - A systematic reviewJakob Starup-Linde, Peter VestergaardEuropean Journal of Endocrinology|August 6, 2015
Management of endocrine disease: Diabetes and osteoporosis: cause for concern?Jakob Starup-Linde, Peter VestergaardEndocrine|March 29, 2024
Serum osteoglycin is stable during various glycemic challenges in healthy menJakob Starup-Linde, Sidse Westberg-Rasmussen, Rikke Viggers, et al.Pageof 52